Naveris Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Naveris Inc. - overview
Established
2017
Location
Natick, MA, US
Primary Industry
Biotechnology
About
Naveris Inc. develops advanced blood testing technologies for early cancer detection, focusing on HPV-related malignancies. Their innovative solutions enhance patient monitoring and treatment response evaluation. Founded in 2017 in Natick, US, Naveris Inc.
specializes in blood testing for cancer detection. The company has secured a total of 4 deals, with the most recent being a Series A funding round on September 19, 2022, raising USD 33. 4 mn led by Gurnet Point Capital alongside BrightEdge Ventures and TechU Ventures. Naveris boasts a current valuation of USD 74.
67 mn. The company is co-founded by Charlotte Kuperwasser and Piyush Gupta, with James McNally serving as CEO. Naveris specializes in advanced blood testing technologies aimed at the early detection of cancers, particularly focusing on human papillomavirus (HPV)-related malignancies. Their flagship product, NavDx®, utilizes a proprietary liquid biopsy method that analyzes tumor-tissue-modified DNA in blood plasma, allowing for highly sensitive detection of cancer in asymptomatic individuals and enabling real-time monitoring of treatment responses and identification of recurrence in patients in remission.
Naveris targets healthcare providers, oncology specialists, and hospitals in the US, focusing primarily on head and neck cancer. Naveris operates a direct-to-consumer and B2B revenue model through its proprietary testing services, specifically the NavDx® test. Revenue is generated through partnerships with healthcare institutions and oncology clinics, which order tests for patients requiring cancer screening or monitoring. These transactions typically involve direct billing to healthcare providers or insurance reimbursement.
The business model emphasizes value-based pricing aligned with patient outcomes and clinical efficacy, supporting Naveris's commitment to enhancing cancer detection and patient management. In September 2022, Naveris Inc. raised USD 33. 4 mn in Series A funding, which will be allocated for advancing its products and services.
The company is focused on introducing new testing technologies and expanding its reach into additional markets. Future plans include targeting further geographic regions within the healthcare sector to broaden its client base and enhance early cancer detection efforts.
Current Investors
Sky Ventures Group, Gurnet Point Capital, R-Cubed Capital Partners
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment
Website
www.naveris.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.